PLX-8394 or PLX-7904 for use in the treatment of BRAF-V600 related diseases

摘要

The present disclosure relates to a subject suffering from or at risk for a BRAF V600 mutation or a BRAF fusion mutation-related disease or condition that does not activate the MAPK pathway or express MAPK pathway genes in cells with wild-type BRAF The present invention provides a method of treatment without inducing the disease.